CY2017029I2 - ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ - Google Patents
ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣInfo
- Publication number
- CY2017029I2 CY2017029I2 CY2017029C CY2017029C CY2017029I2 CY 2017029 I2 CY2017029 I2 CY 2017029I2 CY 2017029 C CY2017029 C CY 2017029C CY 2017029 C CY2017029 C CY 2017029C CY 2017029 I2 CY2017029 I2 CY 2017029I2
- Authority
- CY
- Cyprus
- Prior art keywords
- trifluorothymidine
- anticancer drug
- drug containing
- phosphorylase inhibitor
- thymidine phosphorylase
- Prior art date
Links
- 229940122020 Thymidine phosphorylase inhibitor Drugs 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940041181 antineoplastic drug Drugs 0.000 title 1
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/042,059 US7799783B2 (en) | 2005-01-26 | 2005-01-26 | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| JP2005165156 | 2005-06-06 | ||
| PCT/JP2006/301097 WO2006080327A1 (ja) | 2005-01-26 | 2006-01-25 | α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CY2017029I1 CY2017029I1 (el) | 2018-02-14 |
| CY2017029I2 true CY2017029I2 (el) | 2018-02-14 |
Family
ID=36740357
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100947T CY1119393T1 (el) | 2005-01-26 | 2017-09-07 | ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ |
| CY2017029C CY2017029I2 (el) | 2005-01-26 | 2017-09-07 | ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100947T CY1119393T1 (el) | 2005-01-26 | 2017-09-07 | ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1849470B2 (el) |
| JP (1) | JP5576591B2 (el) |
| KR (1) | KR101468216B1 (el) |
| AU (1) | AU2006209547C1 (el) |
| CA (1) | CA2594713A1 (el) |
| CY (2) | CY1119393T1 (el) |
| DK (1) | DK1849470T4 (el) |
| ES (1) | ES2630002T3 (el) |
| FI (1) | FI1849470T4 (el) |
| HU (2) | HUE033306T2 (el) |
| LT (2) | LT1849470T (el) |
| LU (1) | LUC00036I2 (el) |
| NL (1) | NL300889I2 (el) |
| PL (1) | PL1849470T3 (el) |
| PT (1) | PT1849470T (el) |
| RU (1) | RU2394581C2 (el) |
| SI (1) | SI1849470T1 (el) |
| TW (1) | TWI362265B (el) |
| WO (1) | WO2006080327A1 (el) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| ES2630002T3 (es) | 2005-01-26 | 2017-08-17 | Taiho Pharmaceutical Co., Ltd. | Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| JP5852309B2 (ja) * | 2007-04-25 | 2016-02-03 | サイクラセル リミテッド | 増殖性疾患を治療するためのサパシタビンの使用 |
| KR101616246B1 (ko) | 2008-01-25 | 2016-05-02 | 그뤼넨탈 게엠베하 | 약제학적 투여형 |
| MX2010012039A (es) | 2008-05-09 | 2010-11-30 | Gruenenthal Gmbh | Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio. |
| EP2303283A2 (en) * | 2008-05-15 | 2011-04-06 | Katholieke Universiteit Leuven K.U. Leuven R&D | Anti-cancer combination therapy |
| RU2015138422A (ru) | 2009-07-22 | 2018-12-25 | Грюненталь Гмбх | Стабильная при окислении, прочная на излом лекарственная форма |
| MX2012000317A (es) | 2009-07-22 | 2012-02-08 | Gruenenthal Gmbh | Forma de dosificacion de liberacion controlada extruida por fusion en caliente. |
| CA2808219C (en) | 2010-09-02 | 2019-05-14 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
| ES2487244T3 (es) | 2010-09-02 | 2014-08-20 | Grünenthal GmbH | Forma de dosificación resistente a la manipulación que comprende un polímero aniónico |
| CA2839123A1 (en) | 2011-07-29 | 2013-02-07 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
| AU2012292418B2 (en) | 2011-07-29 | 2017-02-16 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
| EP2746404B1 (en) | 2011-08-16 | 2017-12-06 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer |
| TWI503122B (zh) * | 2012-02-15 | 2015-10-11 | Taiho Pharmaceutical Co Ltd | Oral administration of pharmaceutical compositions |
| TWI526210B (zh) * | 2012-02-15 | 2016-03-21 | Taiho Pharmaceutical Co Ltd | Oral pharmaceutical composition |
| MX356421B (es) | 2012-02-28 | 2018-05-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico. |
| AU2013233226B2 (en) | 2012-03-14 | 2016-05-19 | Nisshin Pharma Inc. | Sulfur amino acid-containing composition |
| CN104394851B (zh) | 2012-04-18 | 2017-12-01 | 格吕伦塔尔有限公司 | 抗篡改和抗剂量‑倾泻药物剂型 |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| AU2013263043B2 (en) | 2012-05-16 | 2016-06-16 | Novartis Ag | Dosage regimen for a PI-3 kinase inhibitor |
| EP2979701B1 (en) * | 2013-03-27 | 2020-08-26 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent including irinotecan hydrochloride hydrate |
| TR201819576T4 (tr) * | 2013-03-27 | 2019-01-21 | Taiho Pharmaceutical Co Ltd | Düşük Dozda İrinotekan Hidroklorid Hidrat İçeren Antitümör Ajanı |
| KR101928618B1 (ko) | 2013-05-17 | 2018-12-12 | 다이호야쿠힌고교 가부시키가이샤 | Tk1 단백질의 발현이 항진된 결장직장암 환자에 대한 치료효과 예측 방법 |
| CA2907950A1 (en) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
| AR096438A1 (es) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso |
| BR112016000194A8 (pt) | 2013-07-12 | 2019-12-31 | Gruenenthal Gmbh | forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila |
| HRP20230523T1 (hr) | 2013-09-06 | 2023-08-04 | Taiho Pharmaceutical Co., Ltd. | Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta |
| CN105934241B (zh) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | 通过低温研磨制备粉末状药物组合物 |
| WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| JP2017516789A (ja) | 2014-05-26 | 2017-06-22 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エタノール過量放出に対して防護されている多粒子 |
| EP3285745A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| CA2998259A1 (en) | 2015-09-10 | 2017-03-16 | Grunenthal Gmbh | Protecting oral overdose with abuse deterrent immediate release formulations |
| EP3400963A4 (en) | 2016-01-08 | 2019-08-21 | Taiho Pharmaceutical Co., Ltd. | ANTITUMOR AGENT CONTAINING AN IMMUNOMODULATOR AND AN ANTITUMOR AMPLIFIER |
| KR102412690B1 (ko) * | 2016-02-05 | 2022-06-23 | 다이호야쿠힌고교 가부시키가이샤 | 중증 신장 기능 장애를 갖는 암 환자에 대한 치료 방법 |
| WO2019124544A1 (ja) | 2017-12-22 | 2019-06-27 | 大鵬薬品工業株式会社 | トリフルリジン及び／又はチピラシル由来の類縁物質の検出方法 |
| US10866219B2 (en) | 2017-12-22 | 2020-12-15 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine- and/or tipiracil-related substance |
| WO2019135405A1 (ja) | 2018-01-05 | 2019-07-11 | 大鵬薬品工業株式会社 | トリフルリジン由来の類縁物質の検出方法 |
| US10816517B2 (en) | 2018-01-05 | 2020-10-27 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine-related substance by high-performance liquid chromatography |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69629156T2 (de) | 1995-03-29 | 2004-05-06 | Taiho Pharmaceutical Co. Ltd. | Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel |
| WO1998013045A1 (fr) * | 1996-09-24 | 1998-04-02 | Taiho Pharmaceutical Co., Ltd. | Inhibiteurs de metastases cancereuses contenant des derives d'uracile |
| ES2630002T3 (es) | 2005-01-26 | 2017-08-17 | Taiho Pharmaceutical Co., Ltd. | Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa |
-
2006
- 2006-01-25 ES ES06712292.9T patent/ES2630002T3/es active Active
- 2006-01-25 JP JP2007500529A patent/JP5576591B2/ja active Active
- 2006-01-25 AU AU2006209547A patent/AU2006209547C1/en active Active
- 2006-01-25 PL PL06712292T patent/PL1849470T3/pl unknown
- 2006-01-25 CA CA002594713A patent/CA2594713A1/en not_active Withdrawn
- 2006-01-25 EP EP06712292.9A patent/EP1849470B2/en active Active
- 2006-01-25 HU HUE06712292A patent/HUE033306T2/hu unknown
- 2006-01-25 LT LTEP06712292.9T patent/LT1849470T/lt unknown
- 2006-01-25 PT PT67122929T patent/PT1849470T/pt unknown
- 2006-01-25 WO PCT/JP2006/301097 patent/WO2006080327A1/ja active Application Filing
- 2006-01-25 SI SI200632192T patent/SI1849470T1/sl unknown
- 2006-01-25 DK DK06712292.9T patent/DK1849470T4/da active
- 2006-01-25 RU RU2007132181/15A patent/RU2394581C2/ru active
- 2006-01-26 TW TW095103114A patent/TWI362265B/zh active
-
2007
- 2007-07-19 KR KR1020077016492A patent/KR101468216B1/ko active IP Right Grant
-
2017
- 2017-07-28 LT LTPA2017024 patent/LTC1849470I2/lt unknown
- 2017-08-01 HU HUS1700032C patent/HUS1700032I1/hu unknown
- 2017-08-08 NL NL300889C patent/NL300889I2/nl unknown
- 2017-09-06 FI FIEP06712292.9T patent/FI1849470T4/fi active
- 2017-09-07 CY CY20171100947T patent/CY1119393T1/el unknown
- 2017-09-07 CY CY2017029C patent/CY2017029I2/el unknown
- 2017-09-29 LU LU00036C patent/LUC00036I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2017029I1 (el) | ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΦΑΡΜΑΚΟ ΠΟΥ ΠΕΡΙΕΧΕΙ α,α,α-ΤΡΙΦΘΟΡΟΘΥΜΙΔΙΝΗ ΚΑΙ ΑΝΑΣΤΟΛΕΑ ΦΩΣΦΟΡΥΛΑΣΗΣ ΘΥΜΙΔΙΝΗΣ | |
| DE112006001565A5 (de) | Nanopartikel-Wirkstoff-Konjugate | |
| EP1952224A4 (en) | APPLICATION FOR THE TAKING OF ACTIVE NOTES | |
| DK1894567T3 (da) | Ledsagende farmaceutiske midler og anvendelse deraf | |
| DK1907037T3 (da) | Medikamentdispenser. | |
| DE602005020310D1 (de) | Lanzette, lanzettenanordnung und lanzette-sensor-kombination | |
| RU2398586C3 (ru) | Фармацевтическая композиция | |
| DK1957073T3 (da) | Lægemiddel | |
| DK2046715T3 (da) | Substituerede 1,3-diphenylpropanderivater, præparater og anvendelser deraf | |
| DK2079485T3 (da) | Phenylpropionamidforbindelser og anvendelsen deraf | |
| BRPI0719398A2 (pt) | Composição farmacêutica. | |
| DK2034015T3 (da) | Immunstimulerende oligonucleotid og farmaceutisk anvendelse heraf | |
| BRPI0715342A2 (pt) | Derivados de 6-carboxi-normorfinano, síntese e usos dos mesmos | |
| DK1757293T3 (da) | Bh4-responsiv hyperphenylalaninæmi-medikamenter | |
| ATE420081T1 (de) | Trifluormethylbenzamidderivate und therapeutische verwendungen dafür | |
| IL198236A0 (en) | Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof | |
| DK1745786T3 (da) | Neuroprotektive forbindelser og farmaceutiske præparater, som omfatter dem | |
| DE602005020457D1 (de) | Master-slave-flip-flop, trigger-flip-flop und zähler | |
| EP2025667A4 (en) | 9, 10-SECOPREGNANDERIVAT AND MEDICINAL PRODUCTS | |
| HK1136159A1 (en) | Tetra-o-substituted butane-bridge modified ndga derivatives, their synthesis and pharmaceutical use | |
| BRPI0614413A2 (pt) | composto, e, composição farmacêutica | |
| ATE420118T1 (de) | Biotinylierte hexadecasaccharide, pharmazeutische zusammensetzungen daraus und deren verwendung | |
| BRPI0614412A2 (pt) | composto, e, composição farmacêutica | |
| IL186851A0 (en) | Styrylsulfonamides, their manufacture and use as pharmaceutical agents | |
| DE602006017569D1 (de) | Pharmazeutische kombinationen mit lamivudin, stavudin und nevirapin |